Search
Displaying 551–560 of 1066 results
-
Dr Daniel C. Chung appointed as Chief Medical Officer of SparingVision
In the PressFormer Spark Therapeutics head of ophthalmic medical affairs, responsible for the development and approval of Luxturna™, to lead development of SparingVision’s proprietary asset, SPVN06, and further pipeline development
-
Very-Long-Chain Polyunsaturated Fatty Acids Improve Vision in Mice with a Form of Stargardt Disease
Research NewsResearchers believe the VLC-PUFAs may benefit people with autosomal dominant Stargardt disease, AMD, and possibly other retinal degenerations
-
Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board
In the PressDevelopment of lead asset SPVN06 to further benefit from high-level Clinical Advisory Board
-
Research News
The company plans to enroll additional patients as young as four years old
-
Genentech’s Faricimab Performs Well in Phase 3 Clinical Trials for Wet AMD
Research NewsCompany will seek marketing approval for the emerging therapy
-
Foundation News
In honor of Rare Disease Day, this February 28th virtual event will raise awareness and fund research leading to treatments and cures for blinding retinal diseases.
-
Beacon Stories
Jenny was diagnosed with retinitis pigmentosa (RP), just like her mom, at the age of 34. In her own words, Jenny shares her experience with being diagnosed with RP and her journey to accepting it with hopefulness.
-
ProQR Completes Enrollment in Phase 2/3 Clinical Trial of RNA Therapy for LCA10
Research NewsCompany also announced progress in enrollment for Phase 1 / 2 clinical trials for emerging USH2A and RHO RNA therapies.
-
REGENXBIO’s Wet AMD Gene Therapy Moving into Phase 3 Trials
Research NewsIn a Phase ½ clinical trial, the emerging treatment reduced the burden of regular anti-VEGF injections
-
About Page
The Foundation’s Strategic Council is a group of young professionals with an affinity to the Fighting Blindness mission and represent the next generation of Foundation leaders.
